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Abstract 
 
 
Genetic factors determining the response to antipsychotic treatment in 
schizophrenia are poorly understood. A new schizophrenia susceptibility 
gene, the zinc-finger gene ZNF804A, has recently been identified. To 
assess the pharmacogenetic importance of this gene, we treated 144 
schizophrenia patients and assessed the response of positive and 
negative symptoms by PANSS. Patients homozygous for the ZNF804A 
risk allele for schizophrenia (rs1344706 AA) showed poorer improvement 
of positive symptoms (7.35± 0.46) compared to patients with a protective 
allele (9.41±0.71, p=0.022). This provides further evidence that ZNF804A 
is of functional relevance for schizophrenia and indicates that ZNF804A 
may be a novel target for pharmacological interventions. 
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Introduction 
 
The unraveling of the genetic causes of schizophrenia is currently 
progressing rapidly. One of the most compelling new schizophrenia 
susceptibility genes is ZNF804A, a zinc finger domain containing gene 
[7, 10]. Replication of the observed association of ZNF804A with 
schizophrenia in further samples has been successful [12, 13, 16]. The 
intronic variant rs1344706 of ZNF804A has been repeatedly found 
associated with schizophrenia [10, 12, 13, 16]. This variation is also 
functional, with significantly increased expression of the A allele of 
ZNF804A, compared to the C allele [12]. Moreover, expression of 
ZNF804A is increased in schizophrenia patients compared to controls, 
although this change did not reach statistical significance [12]. ZNF804A 
is likely to exert a role in neurodevelopment, similar to other zinc finger 
domain containing proteins. 
 
To date, the most robust pharmacogenetic findings for the response to 
antipsychotics have been found for serotonin (5-HT1A, 5-HT2A, and 5-
HT2C), and dopamine receptor genes (DRD2 and DRD3) [1, 8]. 
However, other systems must also be involved to explain the full picture 
of the genetic contribution of the antipsychotic response. We therefore 
assessed whether the schizophrenia susceptibility gene ZNF804A has a 
pharmacogenetic importance. Since previous studies with monoamine 
system genes have shown that a pharmacogenetic role of a given gene 
may be primarily restricted to the positive or negative symptom response 
[8, 11, 14], we queried whether the disease-associated variant of 
ZNF804A exerts an influence on positive or negative schizophrenia 
symptoms.  
  
Materials and Methods 
 
Patients 
 
144 schizophrenia patients admitted to the Department of Psychiatry and 
Psychotherapy of the University of Bonn due to an exacerbation of 
psychotic symptoms were enrolled in the study. All patients gave written 
informed consent to participate in the study. Schizophrenia was 
diagnosed according to the ICD-10 criteria for schizophrenia. All patients 
were of German Caucasian origin. The schizophrenia patients had an 
average age of 33.6 years. 87 patients were male, while 57 patients 
were female. Patients were treated with atypical antipsychotics 
prospectively for four weeks. PANSS positive and negative 
schizophrenia symptoms were scored at the start of treatment, and at 
weeks one and four. The atypical antipsychotics used included 
olanzapine (n=66), amisulpride (n=47), clozapine (n=18), quetiapine 
(n=19), risperidone (n=13), ziprasidone (n=10), aripiprazole (n=7), 
bifeprunox (n=3), and iloperidone (n=1). Some patients were treated with 
more than one atypical antipsychotic. A major advantage of this study is 
that it is a study in in-patients. Therefore, compliance was controlled by 
patients taking the medication under the eyes of the nurse of the ward. 
Moreover, the patients drank some water directly after taking the 
medication. Thus, proper taking of the medication was ascertained. 
Exclusion criteria were pregnancy, contraindication to neuroleptic 
treatment, mental retardation, organic brain disease, substance abuse or 
dependence, and suicidal behavior in previous history. The study was 
approved by the ethics committee of the University of Bonn. 
 Genotyping 
 
The schizophrenia-associated variant of ZNF804A (rs1344706) was 
genotyped by allele discrimination using TaqMan technology. 12.5 ng of 
DNA was used for a TaqMan SNP genotyping assay, employing the 
Applied Biosystems protocol. The assay consisted of the unlabeled 
forward and reverse primers and two reporters that are dye-labeled with 
FAMTM and VIC® and are designed for allelic discrimination of specific 
SNPs. Both alleles were scored in a single well by measuring the 
fluorescence at the end of the PCR using a Tecan Ultra 384 reader 
(Tecan, Crailsheim, Germany). Excitation- and emission-wavelengths for 
the FAM labeled probes were 485 and 535 nm and for the VIC labeled 
probes 535 and 590 nm, respectively. 
 
Statistical analysis 
 
The difference of PANSS negative or positive symptom scores between 
admission and week four, stratified by genotype, were investigated by 
analysis of variance. A Bonferroni correction for multiple testing was 
performed. The level of significance was set at 0.05 (two-tailed). Since 
the seminal study of O’Donovan and colleagues [10] only assessed allele 
frequencies of this very common variant, we chose to focus on the 
homozygous risk allele carriers to enable a meaningful analysis. This 
approach is borne out by subsequent structural neuroimaging studies [3, 
5]. The PANSS positive or negative symptom scores at admission were 
compared between the ZNF804A genotypes by analysis of variance. 
Pearson Chi2 test was conducted to test for the distribution of gender and 
genotype. 
 Results 
 
144 schizophrenia patients admitted to hospital due to an exacerbation 
of schizophrenia symptoms gave written informed consent to participate 
in the study. A description of the clinical and demographic characteristics 
of the patients as well as the genotype frequencies are given in table 1. 
The distribution of the ZNF804A genotypes was in Hardy-Weinberg 
equilibrium (p=0.535). The genotype distribution did not differ with regard 
to gender (p=0.51; df=2) or age (p=0.92; df=2). Moreover, positive 
(p=0.20; df=2) and negative (p=0.53; df=2) PANSS symptom scores at 
baseline did not differ between the genotypes. 
 
The response of the positive and negative symptoms to treatment with 
atypical antipsychotics is shown in figure 1. We calculated the difference 
of the positive or negative symptoms score at admission versus week 4 
for each individual patient. When assessing the response of positive 
symptoms, those patients with the disease-associated genotype AA of 
ZNF804A improved less than those with the other genotypes. Thus, 
patients with the AA genotype showed a mean improvement of 7.35± 
0.46 (mean ± s.e.m.) of positive symptoms, while patients with at least 
one C allele improved by 9.41±0.71 points (mean ± s.e.m.) (p=0.022) 
(figure 1). This difference remained significant after Bonferroni correction 
(p=0.044).  
 
For negative symptoms, patients with the AA genotype improved by 
4.25±0.47 points (mean ± s.e.m.), while patients with at least one C allele 
improved by 5.08±0.5 points (mean ± s.e.m.). The poorer response of 
the negative symptoms of the patients with the disease-associated 
genotype AA was not significant (p=0.236). 
 
In this study, female patients showed superior improvement of 
symptoms, compared to male patients. This held both for positive 
symptoms (p=0.028) and for negative symptoms (p=0.019). Interestingly, 
there was no gender * ZNF804A genotype interaction for positive 
symptoms (p=0.293), while a gender * ZNF804A genotype interaction 
was seen for negative symptoms (p=0.011). Thus, female patients 
carring a C allele experienced an improvement of negative symptoms by 
7.21 points, while females with the AA genotype improved their negative 
symptoms by 4.14 points during the study. 
 
Age of the patients correlated neither with improvement of positive 
symptoms (p=0.394) nor with improvement of negative symptoms 
(p=0.084). While PANSS symptom scores at baseline did not differ 
between the genotypes, as shown above, improvement of positive 
symptom scores stratified by ZNF804A genotype was reduced to a trend 
(p=0.125) when correcting for positive symptom score at baseline as a 
potential confounding factor. 
 
 
Discussion 
 
We have shown that the schizophrenia susceptibility gene ZNF804A 
influences the response of positive symptoms to antipsychotics. The 
disease-associated genotype AA of rs1344706 led to a poorer response 
of the positive symptoms. This indicates that ZNF804A does not only 
influence the development of schizophrenia, but also has a role in the 
response of symptoms. In addition to the effect of ZNF804A on disturbed 
connectivity in the brain of schizophrenia patients [4], this also shows 
that ZNF804A has a functional role in schizophrenia. The present data 
suggest that the ZNF804A protein may be an important target for the 
development of novel pharmacological treatment strategies of 
schizophrenia.  
 
In a large meta-analysis of ZNF804A, which encompassed 18945 
schizophrenia patients and 38675 controls, a detailed search for new 
ZNF804A polymorphisms and a detailed association analysis showed 
that rs1344706 remained the most strongly associated variant in 
ZNF804A [16]. As the authors state, the allelic association at the 
ZNF804A locus is now one of the most compelling in schizophrenia to 
date [16]. The pharmacogenetic findings regarding ZNF804A reported in 
the present study thus show a pharmacogenetic effect of the most robust 
disease-associated variant of ZNF804A.  
 
As a caveat, it should be considered that ZNF804A is one out of 
potentially hundreds or even thousands of schizophrenia risk genes. The 
role of ZNF804A in explaining the pathogenesis of schizophrenia should 
therefore not be overestimated, and the risk of developing schizophrenia 
will probably be determined by ZNF804A in concert with variants in many 
other risk genes.  
 
Regarding the mechanism by which ZNF804A influences the response to 
atypical antipsychotics, two points should be considered. ZNF804A may 
exert its pharmacogenetic effects by a direct involvement in the 
mechanism of action of the drugs. Alternatively, the ZNF804A genotype 
AA may represent a biomarker which defines a distinct subtype of 
schizophrenia that is more resistant to treatment with atypical 
antipsychotics. Elucidation of a possible direct involvement of ZNF804A 
in the mechanism of action of antipsychotic drugs will require knowledge 
on the function of ZNF804A, which is currently not known. Regarding a 
possible distinct subtype of schizophrenia defined by the ZNF804A 
genotype AA, this is an attractive hypothesis which could be assessed in 
future large studies to see whether any psychopathological 
characteristics stand out in these patients, compared to carriers of the 
ZNF804A C allele. We anticipate that it will be possible in several years’ 
time to differentiate between these possible mechanisms. 
 
The ZNF804A variant influences the response of positive symptoms to 
antipsychotics. The 5-HT1A receptor variant C-1019G, on the other 
hand, has been shown to primarily influence the improvement of 
negative symptoms to antipsychotics [8, 11, 14]. Therefore, a picture is 
emerging where variants in some genes appear to moderate the 
response of positive symptoms, while other genes may influence the 
improvement of negative symptoms. It is anticipated that with an 
increasing number of such genes a prediction of the differential response 
of schizophrenia symptoms may eventually become possible. 
 
ZNF804A has been shown to be a risk gene not only for schizophrenia, 
but also for bipolar disorder [10, 15]. ZNF804A is among a growing group 
of genes affecting the risk for both disorders [2, 6, 9, 15]. It will therefore 
be interesting to assess whether ZNF804A also influences the drug 
response in affective disorders. An example in point is the 5-HT1A 
receptor gene, which has a pharmacogenetic role in both schizophrenia 
and depression [8, 11]. 
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 Figure legend 
 
Figure 1: Improvement of positive and negative symptoms. The 
improvement of positive and negative schizophrenia symptoms 
after four weeks of treatment with atypical antipsychotics is shown. 
Patients homozygous for the ZNF804A risk allele for schizophrenia 
(AA) show poorer improvement of positive symptoms compared to 
patients with a protective allele. Means ± s.e.m. are shown.  
 
 
 Table 1: Clinical characteristics of the 144 schizophrenia patients  
  
Genotype AA AC 
 
CC  
Number (%) 65 (45%) 61 (42%) 18 (13%) 
Age (years) +-SD 33.8+-9.6 33.1+-10 33.9+-11.5 
Gender (m;f) 37; 28 37; 24 13; 5 
Positive symptoms (PANSS) at 
baseline +-SD 
21.6+-3.4 23.2+-6.4 22.6+-3.4 
Positive symptoms (PANNS) at 
week 4 +-SD 
14.3+-3 13.6+-2.8 13.7+-2.2 
Negative symptoms (PANSS) 
at baseline +-SD 
21.4+-3.5 21.9+-4.3 20.9+-3.6 
Negative symptoms (PANNS) 
at week 4 +-SD 
17.1+-3.3 16.8+-3.3 16.2+-3.4 
 
 
 
 
